COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma
Status:
Unknown status
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
chemotherapy- and radiotherapy-induced oral mucositis represents a therapeutic challenge
frequently encountered in cancer patients.This side effect causes significant morbidity and
may delay or interrupt the treatment plan, as well reduce therapeutic index. cyclo-oxygenase
2 (COX-2) is an inducible enzyme primarily expressed in inflamed tissues and tumor. COX-2
inhibitors have shown promise as radio- and chemosensitizer and reduce radio-induced
toxicities.
we have conducted a phase III, randomized double blind clinical trial to evaluate the
toxicity and efficacy of celecoxib, a selective COX-2 inhibitor, administered concurrently
with chemotherapy, and radiation for locally advanced head and neck cancer.